Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2025 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the...
March 11, 2025 08:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
February 28, 2025 08:45 ET | Source: AIM ImmunoTech Inc.

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham...
February 26, 2025 13:20 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that...
February 26, 2025 08:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous...
February 25, 2025 08:30 ET | Source: AIM ImmunoTech Inc.

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase...
February 07, 2025 08:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant...
February 05, 2025 08:00 ET | Source: AIM ImmunoTech Inc.

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...
January 23, 2025 08:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the...
January 22, 2025 08:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...

Next Page keyboard_arrow_right